UA92603C2 - Фармацевтическая композиция для лечения тромбоза - Google Patents

Фармацевтическая композиция для лечения тромбоза

Info

Publication number
UA92603C2
UA92603C2 UAA200711762A UAA200711762A UA92603C2 UA 92603 C2 UA92603 C2 UA 92603C2 UA A200711762 A UAA200711762 A UA A200711762A UA A200711762 A UAA200711762 A UA A200711762A UA 92603 C2 UA92603 C2 UA 92603C2
Authority
UA
Ukraine
Prior art keywords
thrombosis
treatment
antagonists
xinhibitors
factor
Prior art date
Application number
UAA200711762A
Other languages
English (en)
Ukrainian (uk)
Inventor
Пол А. Райлли
Джеймс С. Гилберт
Томас Х. Мюллер
Original Assignee
Берингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36423564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA92603(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Берингер Ингельхайм Интернациональ Гмбх filed Critical Берингер Ингельхайм Интернациональ Гмбх
Publication of UA92603C2 publication Critical patent/UA92603C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке описаны новые фармацевтические композиции, которые содержат, по меньшей мере, один прямой ингибитор тромбина и, по меньшей мере, одно дополнительное активное соединение, выбранное из группы, которая включает ингибиторы агрегации тромбоцитов, которые имеют низкую молекулярную массу, гепарины (НММГ) и гепариноиды, а также нефракционированный гепаринин, ингибиторы фактора Ха, объединенные ингибиторы тромбина/фактора Ха, антагонисты фибриногенного рецептора (антагонисты гликопротеина IIb/IIа) и антагонисты витамина K, необязательно с одним или большим количеством фармацевтически приемлемых инертных наполнителей или носителей, предназначенные для лечения тромбоза.
UAA200711762A 2005-03-29 2006-03-27 Фармацевтическая композиция для лечения тромбоза UA92603C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05006711 2005-03-29

Publications (1)

Publication Number Publication Date
UA92603C2 true UA92603C2 (ru) 2010-11-25

Family

ID=36423564

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200711762A UA92603C2 (ru) 2005-03-29 2006-03-27 Фармацевтическая композиция для лечения тромбоза

Country Status (19)

Country Link
US (2) US20060222640A1 (ru)
EP (1) EP1885354A2 (ru)
JP (1) JP2008534552A (ru)
KR (1) KR20070116936A (ru)
CN (1) CN101151030A (ru)
AR (1) AR056291A1 (ru)
AU (1) AU2006228600A1 (ru)
BR (1) BRPI0608656A2 (ru)
CA (1) CA2602563A1 (ru)
CL (1) CL2010000395A1 (ru)
EA (1) EA015122B1 (ru)
IL (1) IL186267A0 (ru)
MX (1) MX2007010664A (ru)
NO (1) NO20074149L (ru)
NZ (1) NZ562775A (ru)
TW (1) TW200722089A (ru)
UA (1) UA92603C2 (ru)
WO (1) WO2006103206A2 (ru)
ZA (1) ZA200706698B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906894B1 (en) 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
IL159273A0 (en) * 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
US20080274166A1 (en) * 2005-06-10 2008-11-06 Transpharma Medical Ltd. Patch for Transdermal Drug Delivery
AR062057A1 (es) * 2006-07-17 2008-10-15 Boehringer Ingelheim Int Uso de los inhibidores directos de la trombina
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
JP5508272B2 (ja) * 2007-10-29 2014-05-28 トランスファーマ メディカル リミテッド 垂直的なパッチ乾燥
WO2010013231A2 (en) * 2008-07-29 2010-02-04 Yeda Research And Development Co. Ltd. Modulation of coagulation factors and effectors of same for control of transplant organ size
US20110150976A1 (en) * 2008-09-10 2011-06-23 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
EP2358367A1 (en) * 2008-11-11 2011-08-24 Boehringer Ingelheim International GmbH Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
AU2009315729A1 (en) * 2008-11-11 2010-05-20 Boehringer Ingelheim International Gmbh Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
TW201031651A (en) * 2008-11-11 2010-09-01 Boehringer Ingelheim Int Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
MX2011006995A (es) 2008-12-30 2011-09-27 Thrombologic Aps Metodos para identificar pacientes criticamente enfermos en riesgo incrementado de desarrollar nsuficiencia organica y compuestos para el tratamiento de la misma.
SG192124A1 (en) 2011-01-25 2013-08-30 Univ Catholique Louvain Compositions and methods for cell transplantation
CN102250099B (zh) * 2011-05-16 2013-10-16 中国药科大学 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
EP2806879B1 (en) * 2012-01-25 2019-03-06 Université Catholique de Louvain Compositions and methods for cell transplantation
WO2014001220A1 (en) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Method for prevention of stroke
EP2722033A1 (en) * 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
WO2014060561A1 (en) * 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
ES2759228T3 (es) 2013-07-05 2020-05-08 Univ Catholique Louvain Medio acondicionado de células madre de hígado de adultos y su uso en el tratamiento de trastornos del hígado
DE102014108210A1 (de) * 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105250286A (zh) * 2015-11-13 2016-01-20 谭惠娟 一种抗血栓组合物
CN108236612A (zh) * 2016-12-27 2018-07-03 李志忠 用于冠脉介入手术中抗凝的组合产品及其用途
WO2020180489A1 (en) * 2019-03-06 2020-09-10 University Of Rochester Anticoagulant compositions and uses thereof
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use
CN115192691B (zh) * 2022-08-31 2025-03-04 晓恩医药包装材料(安庆)有限公司 一种阿加曲班注射液及预灌封注射器

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
NZ286082A (en) * 1995-03-15 1998-09-24 Behringwerke Ag Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19834751A1 (de) * 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9930540D0 (en) * 1999-12-23 2000-02-16 Rhone Poulenc Rorer Pharma Chemical compounds
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
ES2318036T3 (es) * 2001-09-14 2009-05-01 Mitsubishi Tanabe Pharma Corporation Farmacos que comprenden una combinacion de un agente antitrombotico con un derivado de pirazolona.
CA2476054C (en) * 2002-03-07 2011-11-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof
DE10235639A1 (de) * 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
JP2006524203A (ja) * 2003-04-24 2006-10-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トロンビンの過剰形成及び／又はトロンビンレセプターの発現上昇により生じる血栓塞栓性疾病及び疾患の治療及び予防のためのジピリダモール又はモピダモールの使用

Also Published As

Publication number Publication date
EA200701841A1 (ru) 2008-02-28
CN101151030A (zh) 2008-03-26
US20060222640A1 (en) 2006-10-05
BRPI0608656A2 (pt) 2010-01-19
WO2006103206A2 (en) 2006-10-05
US20100184729A1 (en) 2010-07-22
NO20074149L (no) 2007-12-11
TW200722089A (en) 2007-06-16
NZ562775A (en) 2011-03-31
WO2006103206A3 (en) 2007-01-11
KR20070116936A (ko) 2007-12-11
AR056291A1 (es) 2007-10-03
EA015122B1 (ru) 2011-06-30
JP2008534552A (ja) 2008-08-28
IL186267A0 (en) 2008-01-20
CA2602563A1 (en) 2006-10-05
AU2006228600A1 (en) 2006-10-05
EP1885354A2 (en) 2008-02-13
ZA200706698B (en) 2008-12-31
CL2010000395A1 (es) 2010-08-20
MX2007010664A (es) 2007-12-12

Similar Documents

Publication Publication Date Title
UA92603C2 (ru) Фармацевтическая композиция для лечения тромбоза
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
DE60324544D1 (de) Muskarin antagonisten
MX2009005604A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.
WO2009144555A8 (en) Pyrazolospiroketone acetyl-coa carboxylase inhibitors
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
WO2005023761A3 (en) Cytokine inhibitors
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MY145074A (en) Thiazolidin-4-one derivatives
MXPA05009015A (es) Nuevos derivados de bencimidazol e imidazo-piridina y su utilizacion como medicamentos.
SE0302760D0 (sv) New compounds
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
UA98658C2 (ru) Циклические депсипептиды
WO2009065922A3 (de) Organische verbindungen
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
WO2007017728A3 (en) Novel heterocyclic compounds
WO2007066337A3 (en) Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
UA107106C2 (uk) УРЕТАНИ, СЕЧОВИНИ, АМІДИ ТА РОДИННІ ІНГІБІТОРИ ФАКТОРА Xа
ATE282041T1 (de) Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist
WO2009065921A3 (de) Organischeverbindungen
WO2004069145A3 (en) Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
ATE316972T1 (de) Trizyklische crf rezeptor antagonisten